Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?

Inflammatory bowel diseases (IBDs), which include Crohn’s disease and ulcerative colitis, are multifactorial diseases that involve in particular a modification of the gut microbiota, known as dysbiosis. The initial sets of metataxonomic and metagenomic data first made it possible to approximate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacroix, Vickie, Cassard, Alexis, Mas, Emmanuel, Barreau, Frederick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537481/
https://www.ncbi.nlm.nih.gov/pubmed/34681921
http://dx.doi.org/10.3390/ijms222011255
_version_ 1784588261768822784
author Lacroix, Vickie
Cassard, Alexis
Mas, Emmanuel
Barreau, Frederick
author_facet Lacroix, Vickie
Cassard, Alexis
Mas, Emmanuel
Barreau, Frederick
author_sort Lacroix, Vickie
collection PubMed
description Inflammatory bowel diseases (IBDs), which include Crohn’s disease and ulcerative colitis, are multifactorial diseases that involve in particular a modification of the gut microbiota, known as dysbiosis. The initial sets of metataxonomic and metagenomic data first made it possible to approximate the microbiota profile in IBD. In addition, today the new ‘omics’ techniques have enabled us to draw up a functional and integrative map of the microbiota. The key concern in IBD is to develop biomarkers that allow us to assess the activity of the disease and predict the complications and progression, while also guiding the therapeutic care so as to develop personalized medicine. In this review, we present all of the latest discoveries on the microbiota provided by “omics” and we outline the benefits of these techniques in developing new diagnostic, prognostic and therapeutic tools.
format Online
Article
Text
id pubmed-8537481
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85374812021-10-24 Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools? Lacroix, Vickie Cassard, Alexis Mas, Emmanuel Barreau, Frederick Int J Mol Sci Review Inflammatory bowel diseases (IBDs), which include Crohn’s disease and ulcerative colitis, are multifactorial diseases that involve in particular a modification of the gut microbiota, known as dysbiosis. The initial sets of metataxonomic and metagenomic data first made it possible to approximate the microbiota profile in IBD. In addition, today the new ‘omics’ techniques have enabled us to draw up a functional and integrative map of the microbiota. The key concern in IBD is to develop biomarkers that allow us to assess the activity of the disease and predict the complications and progression, while also guiding the therapeutic care so as to develop personalized medicine. In this review, we present all of the latest discoveries on the microbiota provided by “omics” and we outline the benefits of these techniques in developing new diagnostic, prognostic and therapeutic tools. MDPI 2021-10-19 /pmc/articles/PMC8537481/ /pubmed/34681921 http://dx.doi.org/10.3390/ijms222011255 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lacroix, Vickie
Cassard, Alexis
Mas, Emmanuel
Barreau, Frederick
Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?
title Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?
title_full Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?
title_fullStr Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?
title_full_unstemmed Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?
title_short Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?
title_sort multi-omics analysis of gut microbiota in inflammatory bowel diseases: what benefits for diagnostic, prognostic and therapeutic tools?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537481/
https://www.ncbi.nlm.nih.gov/pubmed/34681921
http://dx.doi.org/10.3390/ijms222011255
work_keys_str_mv AT lacroixvickie multiomicsanalysisofgutmicrobiotaininflammatoryboweldiseaseswhatbenefitsfordiagnosticprognosticandtherapeutictools
AT cassardalexis multiomicsanalysisofgutmicrobiotaininflammatoryboweldiseaseswhatbenefitsfordiagnosticprognosticandtherapeutictools
AT masemmanuel multiomicsanalysisofgutmicrobiotaininflammatoryboweldiseaseswhatbenefitsfordiagnosticprognosticandtherapeutictools
AT barreaufrederick multiomicsanalysisofgutmicrobiotaininflammatoryboweldiseaseswhatbenefitsfordiagnosticprognosticandtherapeutictools

Ejemplares similares